CLSD Key Statistics, Chart & Performance
The current stock price of CLSD is 0.41 USD. In the past month the price decreased by -89.12%. In the past year, price decreased by -97.4%.
CLSD Technical Analysis
CLSD Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to CLSD. Both the profitability and financial health of CLSD have multiple concerns.
CLSD Financial Highlights
Over the last trailing twelve months CLSD reported a non-GAAP Earnings per Share(EPS) of -5.19. The EPS increased by 19.53% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -180.75% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
CLSD Forecast & Estimates
11 analysts have analysed CLSD and the average price target is 61.2 USD. This implies a price increase of 14826.83% is expected in the next year compared to the current price of 0.41.
For the next year, analysts expect an EPS growth of 56.93% and a revenue growth 102.46% for CLSD
CLSD Ownership
About CLSD
Company Profile
Clearside Biomedical, Inc. is a biopharmaceutical company that delivers therapies to the back of the eye through the suprachoroidal space. The company is headquartered in Alpharetta, Georgia and currently employs 32 full-time employees. The company went IPO on 2016-06-02. The firm's SCS injection platform, utilizing its patented SCS Microinjector, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a variety of therapies to the macula, retina, or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases. The firm is developing its own pipeline of small molecule product candidates for administration via its SCS Microinjector. The firm's lead program, CLS-AX (axitinib injectable suspension), for the treatment of neovascular age-related macular degeneration (wet AMD). The company developed and gained approval for its product, XIPERE (triamcinolone acetonide injectable suspension) for suprachoroidal use, which is available in the United States through a commercial partner.
Company Info
CLEARSIDE BIOMEDICAL INC
900 North Point Parkway, Suite 200
Alpharetta GEORGIA 30005 US
CEO: George Lasezkay
Employees: 32
Phone: 16782703631
CLEARSIDE BIOMEDICAL INC / CLSD FAQ
What does CLSD do?
Clearside Biomedical, Inc. is a biopharmaceutical company that delivers therapies to the back of the eye through the suprachoroidal space. The company is headquartered in Alpharetta, Georgia and currently employs 32 full-time employees. The company went IPO on 2016-06-02. The firm's SCS injection platform, utilizing its patented SCS Microinjector, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a variety of therapies to the macula, retina, or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases. The firm is developing its own pipeline of small molecule product candidates for administration via its SCS Microinjector. The firm's lead program, CLS-AX (axitinib injectable suspension), for the treatment of neovascular age-related macular degeneration (wet AMD). The company developed and gained approval for its product, XIPERE (triamcinolone acetonide injectable suspension) for suprachoroidal use, which is available in the United States through a commercial partner.
Can you provide the latest stock price for CLEARSIDE BIOMEDICAL INC?
The current stock price of CLSD is 0.41 USD. The price decreased by -26.96% in the last trading session.
Does CLSD stock pay dividends?
CLSD does not pay a dividend.
What is the ChartMill technical and fundamental rating of CLSD stock?
CLSD has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Which stock exchange lists CLSD stock?
CLSD stock is listed on the Nasdaq exchange.
What is CLEARSIDE BIOMEDICAL INC worth?
CLEARSIDE BIOMEDICAL INC (CLSD) has a market capitalization of 2.14M USD. This makes CLSD a Nano Cap stock.
When does CLEARSIDE BIOMEDICAL INC (CLSD) report earnings?
CLEARSIDE BIOMEDICAL INC (CLSD) will report earnings on 2026-03-25, after the market close.